Related references
Note: Only part of the references are listed.Clinical cancer nanomedicine
Joy Wolfram et al.
NANO TODAY (2019)
Protein Toxin Chaperoned by LRP-1-Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo
Yu Jiang et al.
ADVANCED MATERIALS (2018)
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma
Cindy Varga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Current use of monoclonal antibodies in the treatment of multiple myeloma
Cindy Varga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Current Developments in Immunotherapy in the Treatment of Multiple Myeloma
Martin Koehler et al.
CANCER (2018)
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
Pilar de la Puente et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model
Walhan Alshaer et al.
JOURNAL OF CONTROLLED RELEASE (2018)
GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment
Yan Zou et al.
MOLECULAR PHARMACEUTICS (2018)
Advancements in Nanomedicine for Multiple Myeloma
Alexandre Detappe et al.
TRENDS IN MOLECULAR MEDICINE (2018)
Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
S. Manier et al.
NATURE COMMUNICATIONS (2018)
Peptide density targets and impedes triple negative breast cancer metastasis
Daxing Liu et al.
NATURE COMMUNICATIONS (2018)
Progress and challenges towards targeted delivery of cancer therapeutics
Daniel Rosenblum et al.
NATURE COMMUNICATIONS (2018)
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Evangelos Terpos et al.
BLOOD CANCER JOURNAL (2018)
Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016
Andrew J. Cowan et al.
JAMA ONCOLOGY (2018)
Nanomedicines for the treatment of hematological malignancies
Anil K. Deshantri et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Joske Ubels et al.
NATURE COMMUNICATIONS (2018)
Peptide-decorated polymeric nanomedicines for precision cancer therapy
Huanli Sun et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetically Engineered Liposome-like Nanovesicles as Active Targeted Transport Platform
Pengfei Zhang et al.
ADVANCED MATERIALS (2018)
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy
Naoki Hosen et al.
NATURE MEDICINE (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer siRNA Therapy In Vivo
Yan Zou et al.
ADVANCED MATERIALS (2017)
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Qihang Sun et al.
ADVANCED MATERIALS (2017)
Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus
Quanyin Hu et al.
ADVANCED MATERIALS (2016)
Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Yan Zou et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm et al.
NATURE REVIEWS MATERIALS (2016)
Clinical Translation of Nanomedicine
Yuanzeng Min et al.
CHEMICAL REVIEWS (2015)
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Fabian Birzele et al.
CLINICAL CANCER RESEARCH (2015)
Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin
Leila Arabi et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+human breast tumor xenografts
Yinan Zhong et al.
JOURNAL OF CONTROLLED RELEASE (2015)
An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma
Nitya S. Ramadoss et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
The Cyclophilin A-CD 147 complex promotes the proliferation and homing of multiple myeloma cells
Di Zhu et al.
NATURE MEDICINE (2015)
Modulation of CD44 activity by A6-peptide
Malcolm Finlayson
FRONTIERS IN IMMUNOLOGY (2015)
Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo
Jonathan D. Ashley et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
C. C. Bjorklund et al.
LEUKEMIA (2014)
Engineered nanomedicine for myeloma and bone microenvironment targeting
Archana Swami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Systematic Analysis of Peptide Linker Length and Liposomal Polyethylene Glycol Coating on Cellular Uptake of Peptide-Targeted Liposomes
Jared F. Stefanick et al.
ACS NANO (2013)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Monica Casucci et al.
BLOOD (2013)
Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
Noopur Raje et al.
CLINICAL CANCER RESEARCH (2011)
A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
Randolph S. Piotrowicz et al.
MOLECULAR CANCER THERAPEUTICS (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Margot Zoeller
NATURE REVIEWS CANCER (2011)
Correlation of High-Resolution X-Ray Micro-Computed Tomography with Bioluminescence Imaging of Multiple Myeloma Growth in a Xenograft Mouse Model
Andrei A. Postnov et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer
Sharad A. Ghamande et al.
GYNECOLOGIC ONCOLOGY (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
K Mishima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
